BioSight
Companies
Monopar Therapeutics logo

MNPR

NASDAQWILMETTE, IL
Monopar Therapeutics

Monopar Therapeutics develops copper-chelating therapies and radiopharmaceutical therapeutics and imaging agents for clinical use. The excerpt does not provide sufficient information about specific therapeutic areas or the current development stage of their programs beyond references to clinical trials and regulatory submissions, including an NDA planned for a candidate called ALXN1840.

Price history not yet available for MNPR.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar